Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $26.43 Consensus Target Price from Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a consensus recommendation of “Buy” from the five brokerages that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last year is $26.43.

CPRX has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $29.00 price objective on shares of Catalyst Pharmaceuticals in a report on Wednesday, March 27th.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the transaction, the insider now owns 124,433 shares of the company’s stock, valued at approximately $2,045,678.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $31,000. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares during the period. Nisa Investment Advisors LLC boosted its position in Catalyst Pharmaceuticals by 306.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 3,829 shares during the period. Tower Research Capital LLC TRC boosted its position in Catalyst Pharmaceuticals by 84.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 2,833 shares during the period. Finally, Sherbrooke Park Advisers LLC purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $123,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 1.2 %

CPRX opened at $15.05 on Friday. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $17.76. The company has a 50-day moving average price of $15.59 and a 200 day moving average price of $14.68. The company has a market cap of $1.78 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 0.82 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The company had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. As a group, sell-side analysts expect that Catalyst Pharmaceuticals will post 1.81 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.